Daniel Alanine

Dan has worked at the cutting edge of antibody discovery for close to 10 years.

Dan obtained his DPhil in biochemistry and vaccinology at the University of Oxford at the Jenner Institute and Department of Biochemistry. His postdoctoral work was spent discovering monoclonal antibodies for infectious disease, first for malaria in Oxford where he isolated the first fully human monoclonals to malaria vaccine target PfRH5, then for HIV gp120 at Harvard Medical School.

At PetMedix since 2019, Dan is the scientific lead for external programs and currently oversees several discovery projects, canine and feline, spanning multiple disease areas.